Drug consortium seeks trial participants. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Drug consortium seeks trial participants. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Posit Aware. 1995 May/Jun;:9. Unique Identifier : AIDSLINE AIDS/95700403
Grodeck B

Abstract: The Inter-Company Collaboration (ICC) recently announced that it is seeking HIV-positive participants to enroll in the first study of three-drug combinations at several research centers throughout the United States. Formed last April, the ICC is a consortium of 14 international pharmaceutical companies that have agreed to share information and drug supplies to more quickly and efficiently gain data about antiretroviral agents. ICC 001, the ICC's first trial, will evaluate three separate three-drug combinations and AZT, ddC, nevirapine, and a protease inhibitor called saquinavir. The study of 225 people will use viral load, a new DNA technology that will allow researchers to quickly determine the effects of antiretroviral agents. Participants must be 13 years of age or older, have never taken antiretrovirals, and have a T-cell count between 200 and 500. For more information call ICC's coordinating center at (800) 925-2437.
Keywords: Adolescence Adult Aged Antiviral Agents/*THERAPEUTIC USE *Clinical Trials CD4 Lymphocyte Count Drug Therapy, Combination Human HIV Infections/*DRUG THERAPY Middle Age NEWSLETTER ARTICLEKWDadolescenceadultagedantiviralagents/KWDtherapeuticuseKWDclinicaltrialscd4lymphocytecountdrugtherapy,combinationhumanhivinfections/KWDdrugtherapymiddleagenewsletterarticle
951230
M95C3193

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .